Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 9/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 9/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL1245244 | 0.98 | SMYD2 (0.45) | SMYD2CHRM2CHRM3ADRB2 | |
| Trifluoroacetic Acid SCHEMBL6525747 | 0.97 | SMYD2 (0.46) | SMYD2CHRM2CHRM3ADRB2 | |
| SCHEMBL17101374 | 0.95 | SMYD2 (0.46) | SMYD2CHRM2CHRM3ADRB2 | |
| SCHEMBL12847000 | 0.93 | SMYD2 (0.47) | SMYD2CHRM2CHRM3ADRB2 | |
| SCHEMBL12846797 | 0.92 | CHRM2 (0.45) | SMYD2CHRM2CHRM3ADRB2 | |
| SCHEMBL14576249 | 0.92 | SMYD2 (0.50) | SMYD2CHRM2CHRM3ADRB2 | |
| SCHEMBL12847130 | 0.91 | CHRM3 (0.44) | SMYD2CHRM2CHRM3ADRB2 | |
| SCHEMBL12846800 | 0.91 | CHRM2 (0.44) | SMYD2CHRM2CHRM3ADRB2 | |
| Trifluoroacetic Acid SCHEMBL6524593 | 0.90 | SMYD2 (0.46) | SMYD2CHRM2CHRM3ADRB2 | |
| SCHEMBL12847100 | 0.90 | CHRM2 (0.44) | SMYD2CHRM2CHRM3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459572-B1 | SPIROCYCLIC AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2018-09-12 | — | — | EP | claimed |
| WO-2012085582-A1 | COMPOUND | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | claimed |
| US-10954211-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2021-03-23 | — | — | US | disclosed |
| US-20190330187-A1 | Chemical Compounds | ASTRAZENECA UK LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-10336725-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2019-07-02 | — | — | US | disclosed |
| EP-2459572-B1 | SPIROCYCLIC AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2018-09-12 | — | — | EP | disclosed |
| US-20180162838-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2018-06-14 | — | — | US | disclosed |
| EP-3119752-B1 | 3,4-DIAMINO-6-CHLOROPYRAZINE-2-CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF ENAC MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2018-05-16 | — | — | EP | disclosed |
| US-9873678-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2018-01-23 | — | — | US | disclosed |
| US-20170107195-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2017-04-20 | — | — | US | disclosed |
| EP-3119752-A1 | CHEMICAL COMPOUNDS | Astrazeneca AB (SE) | 2017-01-25 | — | — | EP | disclosed |
| US-20130018037-A1 | Compounds - 801 | ASTRAZENECA UK LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| WO-2012085582-A1 | COMPOUND | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085582-A1 | COMPOUND | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | disclosed |
| EP-2459572-A2 | SPIROCYCLIC AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2012-06-06 | — | — | EP | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| WO-2011012896-A2 | COMPOUNDS - 801 | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011012896-A2 | COMPOUNDS - 801 | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107195-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | SMYD2 3156/4885CHRM2 910/4885CHRM3 167/4885 |
| US-10336725-B2 | Chemical compounds | CFTR, SCNN1B, SCNN1A | SMYD2 3156/4885CHRM2 910/4885CHRM3 167/4885 |
| US-20180162838-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | SMYD2 3156/4885CHRM2 910/4885CHRM3 167/4885 |
| US-10954211-B2 | Chemical compounds | CFTR, SCNN1B, SCNN1A | SMYD2 3156/4885CHRM2 910/4885CHRM3 167/4885 |
| US-20130018037-A1 | Compounds - 801 | ADRA2C, ADRB2, ADRB1 | SMYD2 2372/4885CHRM2 157/4885CHRM3 97/4885 |
| US-20190330187-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | SMYD2 3156/4885CHRM2 910/4885CHRM3 167/4885 |
| US-20110053909-A1 | Compounds - 801 | ADRA2C, ADRB2, ADRB1 | SMYD2 2372/4885CHRM2 157/4885CHRM3 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.